A new approach to off-the-shelf T cell therapy for cancer treatment
Official title: Engager T cell: A Simple Solution for Off-the-shelf T Cell Therapy for Cancer
Funded at Immunebro Therapeutics INC. · NIH-10820780 · Data updated 2026-11-12
This study is testing a new type of T cell therapy that aims to help cancer patients by using specially designed T cells that can be made easily and safely, with the hope of treating leukemia more effectively.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunebro Therapeutics INC. NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $361,635 |
| NIH project number | 1R43CA281523-01A1 |
| Project ID | NIH-10820780 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who may benefit from T cell therapies, particularly those with conditions like leukemia.
✕Less likely to help
Patients with cancers that do not respond to T cell therapies or those who are not eligible for any form of T cell treatment may not benefit from this research.
What this research studies
This research focuses on developing a novel type of T cell therapy called engager T cells, which are engineered to target cancer cells without the need for complex gene editing. The approach aims to create donor-derived T cells that can be mass-produced and made readily available to patients, addressing the logistical and economic challenges of current therapies. By using a simpler manufacturing process, this therapy seeks to minimize safety concerns such as the risk of graft versus host disease (GvHD). Preliminary studies have shown promising results in treating leukemia in mouse models, indicating potential effectiveness in humans.
Why it matters
Potential benefit: If successful, this research could provide a more accessible and safer T cell therapy option for cancer patients.
How similar studies have gone: Other research has shown success with similar off-the-shelf T cell therapies, but this specific approach using engager T cells is relatively novel.
Where this research is happening
-
Immunebro Therapeutics INC.
Chicago, United States Active
Researchers
- Principal investigator: Li, Gongbo — Immunebro Therapeutics INC.
- Study coordinator: Li, Gongbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.